Two Cases of Nephrolithiasis Following Administration of Cyclosporine.
- Author:
Ji Young PARK
1
;
Jung Hwa RYU
;
Dong Ryeol RYU
;
Seung Jung KIM
;
Duk Hee KANG
;
Kyun Il YOON
;
Kyu Bok CHOI
Author Information
1. Division of Nephrology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea. kbchoi@ewha.ac.kr
- Publication Type:Case Report
- Keywords:
Cyclosporine;
Citrate;
Nephrolithiasis;
Nephrocalcinosis
- MeSH:
Acidosis, Renal Tubular;
Autoimmune Diseases;
Citric Acid;
Cyclosporine;
Glomerulonephritis;
Glomerulonephritis, Membranous;
Humans;
Immunosuppressive Agents;
Kidney Transplantation;
Nephrocalcinosis;
Nephrolithiasis;
Nephrotic Syndrome;
Organ Transplantation;
Quaternary Ammonium Compounds;
Risk Factors;
Transplants
- From:Korean Journal of Nephrology
2008;27(5):600-605
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Cyclosporine is one of the most useful immunosuppressants for many diseases including nephrotic syndrome, glomerulonephritis, organ transplantation, and other autoimmune diseases. However, cyclosporine is known to cause renal tubular acidosis (RTA) due to a decrease in urinary ammonium excretion. Cyclosporine also can lead to significant hypocitraturia due to a higher proximal tubular reabsorption of citrate and increase the risk for nephrolithiasis. Citrate excretion is essential for the prevention of urinary supersaturation and hypocitraturia is a major risk factor for nephrocalcinosis and nephrolithiasis. Now we report two cases of nephrolithiasis treated with cyclosporine. The first patient is a renal transplantation recipient and the second patient has membranous glomerulonephritis. Therefore, these two cases lead us to conclude that patients treated with cyclosporine have to be regularly followed up for nephrolithiasis caused by cyclosporine-induced tubular dysfunction.
